Last reviewed · How we verify
albumin paclitaxel, cispatin, tislelizumab
albumin paclitaxel, cispatin, tislelizumab is a Targeted chemotherapy, PD-1 inhibitor, platinum-based chemotherapy Small molecule drug developed by Lai-ping Zhong. It is currently in Phase 3 development for Non-small cell lung cancer, gastric cancer, esophageal cancer.
Albumin paclitaxel is a targeted chemotherapy drug that delivers paclitaxel directly to tumors, while tislelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 pathway to enhance anti-tumor immune response, and cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication.
Albumin paclitaxel is a targeted chemotherapy drug that delivers paclitaxel directly to tumors, while tislelizumab is a PD-1 inhibitor that blocks the PD-1/PD-L1 pathway to enhance anti-tumor immune response, and cisplatin is a platinum-based chemotherapy drug that interferes with DNA replication. Used for Non-small cell lung cancer, gastric cancer, esophageal cancer.
At a glance
| Generic name | albumin paclitaxel, cispatin, tislelizumab |
|---|---|
| Sponsor | Lai-ping Zhong |
| Drug class | Targeted chemotherapy, PD-1 inhibitor, platinum-based chemotherapy |
| Target | PD-1, tubulin, DNA |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Albumin paclitaxel uses albumin as a carrier to deliver paclitaxel to tumors, reducing systemic toxicity. Tislelizumab targets the PD-1 receptor on T cells, preventing its interaction with PD-L1 on tumor cells and allowing the immune system to attack cancer cells more effectively. Cisplatin works by forming platinum-DNA adducts that interfere with DNA replication and transcription, leading to cell death.
Approved indications
- Non-small cell lung cancer, gastric cancer, esophageal cancer
Common side effects
- Neutropenia
- Anemia
- Thrombocytopenia
- Nausea
- Vomiting
- Diarrhea
- Fatigue
- Rash
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- albumin paclitaxel, cispatin, tislelizumab CI brief — competitive landscape report
- albumin paclitaxel, cispatin, tislelizumab updates RSS · CI watch RSS
- Lai-ping Zhong portfolio CI
Frequently asked questions about albumin paclitaxel, cispatin, tislelizumab
What is albumin paclitaxel, cispatin, tislelizumab?
How does albumin paclitaxel, cispatin, tislelizumab work?
What is albumin paclitaxel, cispatin, tislelizumab used for?
Who makes albumin paclitaxel, cispatin, tislelizumab?
What drug class is albumin paclitaxel, cispatin, tislelizumab in?
What development phase is albumin paclitaxel, cispatin, tislelizumab in?
What are the side effects of albumin paclitaxel, cispatin, tislelizumab?
What does albumin paclitaxel, cispatin, tislelizumab target?
Related
- Drug class: All Targeted chemotherapy, PD-1 inhibitor, platinum-based chemotherapy drugs
- Target: All drugs targeting PD-1, tubulin, DNA
- Manufacturer: Lai-ping Zhong — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Non-small cell lung cancer, gastric cancer, esophageal cancer
- Compare: albumin paclitaxel, cispatin, tislelizumab vs similar drugs
- Pricing: albumin paclitaxel, cispatin, tislelizumab cost, discount & access